Details for Patent: 11,666,536

Which drugs does patent 11,666,536 protect, and when does it expire?

Patent 11,666,536 protects PYRIDOSTIGMINE BROMIDE and is included in one NDA.

This patent has nineteen patent family members in seven countries.

Summary for Patent: 11,666,536

Title:	Extended release compositions comprising pyridostigmine
Abstract:	Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.
Inventor(s):	Siva Ram Kiran Vaka, Dipen Desai, Wantanee Phuapradit, Navnit H. Shah, Namdev B. Shelke
Assignee:	Amneal Complex Products Research LLC
Application Number:	US17/550,117
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 11,666,536

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amneal	PYRIDOSTIGMINE BROMIDE	pyridostigmine bromide	TABLET, EXTENDED RELEASE;ORAL	217604-001	Oct 4, 2024		DISCN	No	No	11,666,536		Y

International Family Members for US Patent 11,666,536

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3031412
Canada	3061382
China	110996922
Denmark	3609472
Denmark	3648747
Denmark	3824881
European Patent Office	3609472